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Introduction
The rarely viral infections, the complications caused by
them are more frequently treated in the ICU (intensive
care unit): flu, respiratory syncytial virus, varicella zoster,
cytomegalovirus, Epstein-Barr virus, adenovirus, severe
acute respiratory syndrome. The structure, transmission,
or immunological background of the pathogen could
play a major role in the variety of the clinical picture or
the disease’s outcome [1]. Nowadays, the epidemics are
more frequently caused by pathogens which are not so
well known. The world paid attention to the WNV (West
Nile virus) infections only in 1999, when 62 cases of
meningoencephalitis were registered in New York State.
At present, there is no kind of etiologic treatment or pro-
phylaxis developed against the WNV. The infection
caused by the WNV is by far more aggressive in solid
organ transplanted patients, with higher mortality [2, 3].
The early goal-specific treatment is performed with im-
munoglobulin and interferon; otherwise the therapy is
mainly supportive.
Case Report
A 52-year-old uremic patient had a first kidney trans-
plantation in 1994 for which chronic allograft nephro -
pathy developed, and hence the patient received the sec-
ond kidney transplantation in 1998 (the first graft was
not removed). In October of 2008, the patient was
 admitted at the department of transplantation because
of fever >39 °C associated with epigastrial pain, diarrhea
and oliguria. The early goal-specific therapy was done
according to the international guidelines for manage-
ment of severe sepsis and septic shock (empirical anti -
biotic therapy – moxifloxacin completed with the re -
duction of the immunosuppressive drugs dose –
cyc lo sporine and mycophenolat mofetil). The different
analyses of cultures, laboratory tests, chest X-ray, and ab-
dominal ultrasound result were negative. The continu-
ously febrile patient’s health condition, especially the
neurological status, deteriorated in spite of the treat-
ment. The patient was transferred at the ICU on the
fourth treatment day with Cheyne–Stokes breathing, a
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SOFA (Sequential Organ Failure Assessment) score: 11,
an APACHE II (Acute Physiology And Chronic Health
Evaluation) score: 14, and Glasgow Coma Scale: 2–3–3;
mechanical ventilation was started with invasive hemo-
dynamic monitoring.
The empirical antibiotic therapy was switched on
(meropenem, ampicillin-sulbactam, metronidazole) and
was completed with antifungal and antiviral therapy (acy-
clovir, fluconazole). The immunosuppressant therapy was
converted first to prednisolone (30 mg/day), then to hy-
drocortisone mono-therapy (200 mg/day). Using a total
body computer tomography (CT) scan done to detect
the reason for septic-toxicity, only the primary graft was
found morbid, and hence graftectomy was performed.
The pathological examination found severe graft impair-
ments: total glomerular destruction, and effusion with
chronic inflammation. The patient’s health condition did
not improve postoperatively; besides rising inflammatory
tests and continuous fever, a neck restriction movement
occurred. The second cranial CT scan was negative apart
from the tighter liquor spaces (see Fig. 1).
The bacterial meningitis was excluded by the neuro-
logical examination, and the analysis of the liquor, but
the viral or fungal etiology, was postulated. In the absence
of known pathogen (repeated cultures, viral screenings
with negative result), intravenous immunoglobulin ther-
apy was started (Pentaglobin®, Biotest). The patient
shortly became afebrile, and hence after five days of treat-
ment this was stopped. In the course of the serological
investigation, increasing titers of specific WNV antibody
(IgG≥1:10 and IgM≥1:320) were detected from both
serum and liquor.
Cerebral magnetic resonance imaging (MRI) investi-
gation was done on the 10th treatment day without any
pathological findings; the electroencephalography per-
formed justified right hemisphere and mesodience -
phalon functional disorder. Parallel to the applied treat-
ment, the patient’s health condition improved rapidly,
he regained consciousness, the inflammatory parameters
returned to normal, and he was successfully extubated
on the 11th treatment day. The patient was transferred
after 20 ICU treatment days to the nephrology depart-
ment from where he departed home with good graft
function and without any neurological deficit after two
more weeks of follow-up care (WNV-specific IgG
titer≥1:320). Throughout, the patient had a good graft
function with the steroid mono-therapy; the original
combined immunosuppression was applied on 23th
treatment day (see Fig. 2).
The origin of WNV infection remained obscure, the
patient did not receive blood component transfusion, and
he was not in direct contact with birds or domestic ani-
mals. The WNV check up was performed also to the
members of his family with negative result. Therefore, it
is supposed that the source of WNV encephalitis was
mosquitoes.
Discussion
The WNV was discovered in 1937 in the West Nile ter-
ritory of Uganda. The infection spread from Africa to
the Near-East, then to Europe, and afterwards to the
rest of the world. Between 1937 and 1990 a smaller
number of infections with moderate fever were re-
ported, but after 1990 several thousand of WNV infec-
tions were registered (Romania, 1996; Russia, 1999; Is-
rael, 2000; Uni ted States, 2002; Canada, 2002) [4]. In
Hungary, according to the available data, annually only
few WNV infections are registered. Between 2003 and
2010 an average of 10 illnesses per year were reported,
but the number of WNV cases are changing year by
year. In the organ transplantation field, our reported
kidney transplanted patient is the first verified WNV case
in Hungary (2008).
The WNV is a positive RNA virus and belongs to the
Flaviviridae family, Flavivirus genus. Actually, two ge-
netically different West Nile viruses are well known, the
human infections are caused by both of them. The pri-
mary carriers are the wild birds; however, different do-
mestic animals (horse, dog) which live in the human
neighborhood could also be infected with the virus [4].
The vectors of the pathogen are different mosquitoes
Fig. 1. Tighter liquor space, else a negative cranial CT scan
species (Culex) that mostly pass the virus in the bird–
mosquito–bird cycle. The humans get in the cycle only
accidentally. The epidemic yearly cycle is determined by
the mosquitoes activity – this is usually between July and
October. The virus spreads from human to human only
accidentally by blood component transfusion, organ
transplantation, or across the placenta and by breast
feeding [5, 6]. The infection incubation time is between
2 and 14 days, and in 20% of the infected only moderate
fever (3–6 days) is developed. In the mild form of the
infection, weakness, malaise, lack of appetite, sickness,
emesis, ocular pain, headache, muscular pain, and
swelling of lymphatic glands can occur, but the upper
respiratory catarrh is also common. In 0.1–0.5% of the
patients, an aggressive form of the infection could be
seen with meningitis, encephalitis, and flaccid paresis or
paralysis. The unconsciousness is accompanied often
with cranial nerve inflammation, epilepsy, rarely with
chorioiditis, vitritis and chorioretinitis. In the cases re-
ported in literature, there are also severe complications
of the WNV infection like myocarditis, pancreatitis and
fulminant hepatitis [4].
It is important to emphasize that in the presence of im-
munosuppression the incubation time is longer: about 3
weeks; the course of the disease could be: 1–2 weeks; the
frequency of severe neurological infection is much higher:
40% and it could lead to a fatal end. The cause of death
can occur by neuronal dysfunction, cerebral edema and
respiratory insufficiency [5].
The WNV infection can be diagnosed by detecting an-
tiviral antibodies (IgM and IgG) or viral RNA (nucleic
acid amplification testing) from the blood or liquor [7].
The IgM is detectable after the first week of disease and
remains positive 6 months after WNV infection. Unfor-
tunately, there is an antigen similarity in the Flavivirus
genus and this can cause positive IgM serological result
for a brief period after yellow fever vaccination. The organ
and blood donor’s screening by detecting the specific an-
tiviral antibodies is not a routine procedure [8]. The
liquor characteristic alteration is pleocytosis, neutrophilia
and increased proteins [9]. The cranial CT scanning and
MRI investigation usually are negative, rarely is thicken-
ing of the meninx or the lesion of the thalamus, pons,
cerebellum and basal ganglions found [10–12]. The dis-
ease has no vaccination prophylaxis or specific treatment;
therefore, the therapy is mainly supportive. Certainly,
there are investigations with several antiviral products
such as purine, pyrimidine analogues, or alpha, beta in-
terferon or intravenous immunoglobulin [2, 5]. The role
of immunoglobulin in the WNV infection therapy is not
proved; nevertheless, based on different recovery case re-
ports it may be presumed that the treatment is efficient
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Fig. 2. Improvement of the clinical condition as the result of the treatment applied in West Nile virus-induced encephalitis. IVIG: intravenous
immunoglobulin
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and in the absence of a specific therapy at present it is the
single applicable treatment possibility [3].
The animal WNV infection experiments have demon-
strated that apart from the cytotoxic T lymphocytes, the
humoral response also has a crucial role in the early
phase of the disease [3, 11]. Similar animal experiments
have proved that intravenous immunoglobulin products
made from healthy Israeli people blood provide 100%
defense against WNV infection depending on dosage
and treatment time. On the contrary, the intravenous
immunoglobulin products made from healthy US peo-
ple blood have 0% defense property [13, 14].
In summary, in the case of an unknown etiology or a
therapy-resistant fever, it is worthwhile to extend the
screening also to WNV. The 2008 United States proto-
cols advise the exclusion of WNV infection in every
febrile transplanted patient or in the presence of im-
munosuppression [15]. The lesson of this case justifies
the need of WNV investigation in febrile transplanted pa-
tients also in Hungary as well. According to the animal
experiments and recovery case reports, in the early phase
of the disease, the 10 days treatment with intravenous im-
munoglobulin products is beneficial.
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